Umar Testing
Testing
Testing
2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.
2023 marked the beginning of a new phase of growth. With four potential launches in 2024, we are focused on excellence, execution and rapidity. Our progress to date demonstrates that our strategy is delivering, leading to a stronger, more resilient Ipsen.
The acquisition of Albireo and the integration of over 25 new programs into our pipeline since 2020 will enable us to continue to deliver groundbreaking therapies to patients worldwide in the coming years.
Beyond financial achievements, we demonstrated a profound commitment to sustainability through our Generation Ipsen strategy. We achieved a 36% reduction in Scope 1 and 2 emissions and a 29% reduction in Scope 3 emissions, and set ambitious goals to become carbon neutral by 2025 and reach net-zero emissions by 2045.
Our journey in 2023 is a story of transformation, innovation, and unwavering dedication as we Focus. Together. For patients and society.
Discover more about our journey and innovations.
Test Story for Rating component
template
Testing video 3 event card
Testing video 2
Testing video 1
Testing
Ipsen’s partnership with Marengo
Ipsen’s 2022 Integrated Annual Report now available
Applications now open for the 2023 Golden Ticket Competition
